Recent studies have indicated that the histone deacetylase inhibitor trichostatin A works synergistically with lapatinib, a HER2 tyrosine kinase inhibitor, to inhibit breast cancer in vitro and in rodent models. Here, ERBB2 is linked to breast cancer.